Polypharmacy: survey of strategies and actions across London

Tell the London RMOC about your approaches to tackling inappropriate polypharmacy. Organisations across London are invited to complete this survey by the 9th February 2018 to inform the work of the London RMOC on this important issue.

There was an error on your page. Please correct any required fields and submit again. Go to the first error

The name of your organisation

Type of organisation

CCG

Commissioning Support Unit

Community Pharmacy

Education Organisation

GP Surgery

NHS England Region

NHS Trust

Other (please specify):

This is required

To what extent is polypharmacy considered a priority within your organisation?

Part of the key deliverables

Subsection of one organisational priority

Not specifically mentioned in organisational objectives

Other (please specify):

This is required

To what extent is polypharmacy a priority across the STP in which your organisation sits?

Part of the key deliverables

Subsection of one organisational priority

Not specifically mentioned in organisational objectives

Other:

This is required

Comments on Priorities

This is required

Which external partners are you engaged with on this work?

Other CCGs in STP

Local AHSN

Universities

3rd Sector

Patient Groups

Other (please specify):

This is required

What services in your locality are designed to address prescribing of more medicines than are clinically required (problematic pharmacy)?

Medication review for people on more than a specific number of medicines

Frailty services which include medicines

Medication review for people at higher risk of medication-related problems

Other (please specify):

This is required

What were the reasons for your specific choice of the type of service?

Previous service evaluation

National/Expert practice guidance

Experience or knowledge of similar service elsewhere

Recognised problem in this locality

Published evidence

Other (please specify):

This is required

Is your service either specifically commissioned, part of a broader package of MO support, or provided in some other way? Please describe.

Is the service spread across a CCG or STP population, or is confined to a particular distinct locality? Please describe.

How do you identify your cohort of service users (data, systems)?

More than 10 Medicines

Over 75 years

E-Frailty Index

PEONY

QAdmissions

PINCER

Varies across the CCG

No specific Tool

Other (please specify):

This is required

What tools do you use, if any, to manage people at risk of medicines-related problems as part of medication review?

STOPP/START

Anticholinergic burden scale

NO TEARS

Presqipp IMPACT

Varies across the organisation

No specific tool

Other (please specify):

This is required

What data categories are being captured?

Harm prevented

Reduction in preventable (potential) medicines-related admissions and readmissions

Reduction in unscheduled preventable medicines-related episodes of care

Clinical interventions

Medicines costs

Medicines started

Medicines stopped

Other (please specify):

This is required

What impact is being measured?

Reduced/prevented harm

Reduced costs

Patient satisfaction

Preventable medicines-related hospital admission/episodes of care

Other (please specify):

This is required

How do you extrapolate impact across your organisation? e.g.

Calculations for costs/impact across organisation

Risk reduction calculation

Other (please specify):

This is required

What staff resource, and in particular what skill mix, does the service require?

Your contact details:
These details will only be used if we need further information from you about this survey.

This question requires an answer

Name

Role

Telephone

Page 1

The name of your organisation

Type of organisation

To what extent is polypharmacy considered a priority within your organisation?

To what extent is polypharmacy a priority across the STP in which your organisation sits?

Which external partners are you engaged with on this work?

What is the location of your service?

What services in your locality are designed to address prescribing of more medicines than are clinically required (problematic pharmacy)?

What were the reasons for your specific choice of the type of service?

Is your service either specifically commissioned, part of a broader package of MO support, or provided in some other way? Please describe.

Is the service spread across a CCG or STP population, or is confined to a particular distinct locality? Please describe.

How do you identify your cohort of service users (data, systems)?

What tools do you use, if any, to manage people at risk of medicines-related problems as part of medication review?

What data categories are being captured?

What impact is being measured?

How do you extrapolate impact across your organisation? e.g.

What staff resource, and in particular what skill mix, does the service require?

Your contact details:These details will only be used if we need further information from you about this survey.

Your contact details:
These details will only be used if we need further information from you about this survey.